Brief: Egetis Says New Data Confirms Safety Of Emcitate In MCt8 Deficiency

Egetis Therapeutics AB (publ)

25/10/2021 07:02

Oct 25 (Reuters) - Egetis Therapeutics AB (publ)  EGTX.ST :
    * NEW DATA CONFIRMS LONG-TERM EFFICACY AND SAFETY OF
EMCITATE® IN
MCT8 DEFICIENCY PATIENTS
    * DATA COMES FROM AN INVESTIGATOR-INITIATED REAL-LIFE COHORT
STUDY
AT 33 SITES CONDUCTED BY ERASMUS MEDICAL CENTER, ROTTERDAM,

Source text for Eikon:  ID:nMFN8nkpF2 
Further company coverage:  EGTX.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))